Introduction
The WT1 tumor suppressor gene encodes a transcriptional regulatory protein that binds DNA via four carboxyl-terminal zinc-fingers. 1, 2 Extensive processing of the WT1 mRNA, including RNA editing 3 and two alternative splices, 4 results in the expression of multiple protein isoforms. Alternative splice I inserts or removes exon 5, which is located in the transcriptional regulatory domain, and alternative splice II results in the insertion of three amino acids (KTS) between the third and fourth zinc-fingers. The presence or absence of exon 5 modulates the transcriptional regulatory activity, 5 while the KTS insert affects DNA binding specificity and subcellular localization. 4, [6] [7] [8] WT1 is expressed in CD34+ hematopoietic progenitor cells. All four major splice forms are expressed, and WT1 expression is downregulated with differentiation. 9, 10 The role of WT1 in hematopoiesis has been investigated in several leukemic cell lines with results that appear to be cell line specific. [11] [12] [13] [14] [15] [16] Experiments using a nontransformed cell line, such as 32D cl3, may more accurately reflect the function of WT1 in normal hematopoiesis. 32D cl3 cells are interleukin-3 (IL-3) dependent, differentiate in response to granulocyte-colony stimulating factor (G-CSF), 17, 18 and do not express endogenous WT1. 19 Inoue et al. 19 demonstrated that overexpression of the WT1 isoform containing both exon 5 and the KTS insert (designated WT1 (+/+)) blocks G-CSF-mediated granulocytic differentiation of these cells. 19 The effect of the three other WT1 isoforms remains unknown. In this study, we examined the effect of the isoform lacking both exon 5 and the KTS insert (designated WT1 (À/À)) on the differentiation of 32D cl3 cells, using a plasmid encoding WT1 (À/À) under the regulation of the zinc-inducible metallothionein (MT) promoter.
Materials and methods

Cell lines and plasmids
32D cl3 cells were grown in Iscove's modified Dulbecco's medium supplemented with 10% heat-inactivated fetal calf serum and 1 ng/ml IL-3 (R&D Systems, Minneapolis, MN, USA). Cell morphology was evaluated after treatment with G-CSF (20 ng/ml; R&D Systems). Cells were attached to glass slides using a cytospin apparatus (Shandon, Pittsburgh, PA, USA), and stained using Wright's/Giemsa stain. In cultures demonstrating rapid growth, cells were enumerated with a Coulter counter, while in cultures containing dying cells, cells were counted with a hemocytometer, using Trypan blue exclusion to verify viability. The plasmids pMTWT(À/À), which contains the cDNA encoding human WT1 (À/À) cloned downstream of the sheep MT promoter, and pMTCB6, the empty vector, were a gift from Dr F Rauscher (Wistar Institute, Philadelphia, PA, USA).
Transfection
32D cl3 cells were transfected using TransIT LT-1 (PanVera, Madison, WI, USA) following the manufacturer's protocol. 10 6 cells were transfected with 15 mg of pMTWT(À/À) or with pMTCB6, the identical plasmid lacking a cDNA insert. After 24 h, cultures were divided in half. One-half was propagated in growth medium supplemented with 1 mg/ml G418 (Invitrogen, Gaithersburg, MD, USA). The other half was split into 96-well plates and also selected for resistance to G418.
Western blotting
Total cellular protein was isolated from cell lines by solubilizing cells in 1 Â Laemmli sample buffer and boiling for 5 min. Protein was quantified using the Noninterfering Protein Assay (Geno Technology, St Louis, MO, USA). In total, 15 mg of protein per lane was used for standard SDS-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose using the Mini-PROTEAN II system (Bio-Rad, Hercules, CA, USA). Blocking with 5% nonfat dried milk prevented nonspecific protein binding. Antibodies against both human and murine WT1 (C-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-actin (Sigma, St Louis, MO, USA), and horseradish peroxidase-conjugated secondary antibodies (Amersham, Piscataway, NJ, USA) were used, and antibody binding was revealed by enhanced chemiluminescence (ECL Western blotting analysis system, Amersham).
RT-PCR
Total RNA was extracted in TriReagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's protocol, and random primed cDNA was reverse transcribed using Superscript II (Invitrogen) according to the manufacturer's protocol. The sequences of the primers used are as follows: for amplifying b-actin, 5 0 -GTGGGCCGCTCTAGGCACCAA-3 0 (sense) and 5 0 -CTCTTTGATGTCACGCACGTATTC-3 0 (antisense); for amplifying gelatinase, 5 0 -ACGGTTGGTACTG-GAAGTTCC-3 0 (sense) and 5 0 -CCAACTTATCCAGACTCCTGG-3 0 (antisense). Amplification was performed using a hotstart protocol: samples were heated to 941C for 4 min and then cooled to 801C prior to the addition of Taq polymerase (RedTaq, Sigma). Samples were then heated to 941C for 15 s followed by 591C for 30 s and then 721C for 45 s for 30 cycles. PCR products were resolved by electropheresis, using a 2% agarose gel.
Northern blotting
Total RNA was extracted as described above. After electrophoresis through a 1.5% agarose gel in MOPS buffer with 6.7% formaldehyde, RNA was transferred to nitrocellulose. Blots were hybridized with probes specific for myeloperoxidase (MPD) and lactoferrin (LF), 20 labeled with [ 32 P]a-dCTP by random priming using standard techniques.
Flow cytometry
Cells were incubated with either phycoerythrin-conjugated antiGr-1 or the isotype control (Becton Dickinson, San Jose, CA, USA) at 41C for 30 min, then washed with phosphate-buffered saline (PBS) and fixed with 1% paraformaldehyde in PBS. Flow cytometric analysis was performed using a BD-LSR FACS machine (Becton Dickinson) and the CellQuest program (Becton Dickinson). In all, 10 000 positive events were analyzed in each sample. For each data point, both unstained cells and cells stained with the isotype control were also used as negative controls. Apoptosis was evaluated using the Annexin-V-Fluo Staining Kit (Roche Diagnostics, Indianapolis, IN, USA). For cell cycle analysis, cells were rinsed once with PBS and fixed in a solution of 0.6% NP40, 3.7% formaldehyde, and 0.01 mg/ml Hoechst 33258 (Sigma) in PBS. Cells were stored at 41C and then analyzed on the BD-LSR FACS machine.
Statistical analysis
Differences in differentiation status among cell lines were analyzed for statistical significance by using the w 2 test.
Results
Generation of stably transfected cell lines
For the generation of stably transfected cell lines, 32D cl3 cells were transfected with pMTWT(À/À) containing the WT1 (À/À) cDNA under the control of the MT promoter. Control cells were transfected with the identical plasmid (pMTCB6) lacking the insert. Half of the pMTWT(À/À)-transfected cells were plated in a mass culture and selected for resistance to G418. This population was designated 32DWT1. From the other half of the original culture, individual G418-resistant clones were isolated by limiting dilution; clones 32DWT2 and 32DWT3 were used in the experiments described here. G418-resistant cell lines containing the empty expression vector were cloned by limiting dilution and designated 32DV1, 32DV2, 32DV3, and 32DV4. These control cell lines were indistinguishable from each other and from untransfected 32D cl3 cells, so only results using 32DV4 are presented here. Whole-cell lysates of the cell lines were subjected to Western blot analysis to determine the level of WT1 expression using an antiserum that detects both human and murine WT1. In the absence of ZnCl 2 To confirm that the morphologic changes reflect a normal pattern of differentiation, several stage-and lineage-specific molecular markers were evaluated. Gr-1 is a cell surface antigen expressed by mature granulocytes. Grown in IL-3 for 7 days, none of the cell lines expressed Gr-1 (data not shown). ZnCl 2 augmented Gr-1 induction by G-CSF in 32DWT1 cells (Figure 4a ), but had no effect on 32DV4 cells (Figure 4a) . Identical results were obtained with 32DWT2 cells (data not shown). In each condition, the percentage of cells expressing Gr-1 is less than the percentage of 'mature cells' as presented in Table 1 . This discrepancy results from the smaller proportion of cells that express sufficient Gr-1 to stain brighter than background staining and from the fact that 'mature cells' include both band forms and polymorphonuclear leucocytes and only the latter cells stain with anti-Gr-1.
In addition to Gr-1, we also evaluated the expression of stageand lineage-specific genes. 32DWT2 cells were chosen for these experiments because these differentiated cells showed superior survival compared with differentiated 32DWT1 cells, facilitating the accumulation of sufficient RNA for analysis. We examined the mRNA expression of MPO, a component of the primary granules of polymorphonuclear cells, as well as neutrophil gelatinase and LF, which are components of secondary granules. 28S rRNA was analyzed as a loading control. MPO expression was rapidly upregulated by G-CSF, in the presence or absence of ZnCl 2 , in both control and WT1 (À/À)-expressing cells (Figures  4b and c) . In contrast, LF expression was induced by G-CSF much more rapidly in 32DWT2 cells treated with ZnCl 2 . G-CSF treatment for 7 days was required to induce the expression of LF in 32DV4 cells in the presence or absence of ZnCl 2 ( Figure 4b ). Strikingly, 32DWT2 cells treated for just 1 day with both G-CSF and ZnCl 2 expressed a significant amount of LF, whereas G-CSF alone induced LF in these cells with kinetics that were indistinguishable from control, with a peak at 7 days (Figure 4c ).
Neutrophil gelatinase is another component of secondary granules. Like LF, gelatinase was induced by G-CSF more rapidly in 32DWT2 cells than in control cells in the presence of ZnCl 2 . As judged by RT-PCR, gelatinase RNA was induced after 3 days of G-CSF treatment in 32DV4 cells. Addition of ZnCl 2 did not affect gelatinase induction in these cells. Treatment of 32DWT2 cells with ZnCl 2 and G-CSF resulted in the expression of neutrophil gelatinase RNA after just 1 day (Figure 4d ). There was very low-level expression of gelatinase in 32DWT2 cells treated with G-CSF alone for 1 or 2 days, and by day 3 expression was comparable to that seen in control cells. Thus, the effect of WT1 (À/À) on the expression of neutrophil gelatinase is similar to the effect on LF.
Induction of WT1 (À/À) slows progression through the cell cycle
Terminal granulocytic differentiation requires an arrest in the G1 phase of the cell cycle. Since WT1 (À/À) represses the gene encoding Cyclin E, a critical mediator of progression from the G1 to the S phase of the cell cycle, we hypothesized that slowing of cell cycle progression might contribute to the ability of WT1 (À/À) to potentiate granulocytic differentiation of these cells. 32DV4 and 32DWT1 cells were grown in IL-3 or in G-CSF, with or without 100 mM ZnCl 2 , for 2 days and cell cycle analysis was performed. After 2 days in G-CSF, the ratio of 32DV4 cells in G1 to cells in S was 1.97, and that ratio was 2.1 for cells in G-CSF and ZnCl 2 ( Table 2 ). In contrast, the G1/S ratio was 3.5 for 32DWT1 cells grown in G-CSF, and 4.4 for the cells grown in G-CSF and ZnCl 2 ( Table 2 ). These findings are consistent with increased accumulation of cells in the G1 phase, and provide a potential mechanistic explanation for our observation that WT1 (À/À) accelerates the differentiation of 32D cl3 cells. Of note, WT1 (À/À) did not affect G1 to S cell cycle progression of 32DWT1 cells in IL-3 (data not shown), consistent with its inability to slow the growth of these cells in IL-3 ( Figure 2 ). Growth of Cells in G-CSF ) and (c), cell number was determined using a Coulter counter, while for (a) cells were counted with a hemocytometer, and exclusion of Trypan blue was used to ensure that only viable cells were counted.
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Discussion
In this study, we examined the effect of WT1 (À/À) expression on the differentiation of 32D cl3 cells. The data presented here, evaluating morphology, gene expression, and antigen expression, strongly support the conclusion that this isoform of WT1 augments the differentiation of 32D cl3 cells treated with G-CSF. This effect was observed in a polyclonal cell line and confirmed in two independently derived clonal lines. Furthermore, our observation that induction of WT1 (À/À) increases the accumulation of G-CSF-treated cells in the G1 phase of the cell cycle provides a potential mechanism for our findings. Results related to ours were recently reported using primary hematopoietic progenitor cells. 15 Retrovirus-mediated expression of WT1 (À/À) resulted in a modest increase in Gr-1 expression, suggesting that WT1 mediates granulocytic differentiation. An alternative explanation, however, would be an Figure 3 Morphologic differentiation of transfected 32D cl3 cells. Photomicrographs of 32DV4 (a) and 32DWT1 (b) cells grown in G-CSF and 100 mM ZnCl 2 for 4 days. Cells were processed by performing a cytospin onto glass slides, fixing in air, and staining with Wright's stain. Table 1 Quantification of differentiation of 32D cl3 cell lines Immature  Intermediate  Mature   32DV4+G-CSF  60  33  6  32DV4+G-CSF+ZnCl 2  73  25  5  32DWT1+G-CSF  45  42  25  32DWT1+G-CSF+ZnCl 2  18  25  61 The indicated cell lines were treated with G-CSF for 4 days with or without 100 mM ZnCl 2 and the percentage of cells with different morphologic characteristics was quantified. Immature cells were predominantly blast forms. Intermediate refers to cells with an eccentric nucleus and neutrophilic cytoplasm containing granules. Mature cells were band forms or polymorphonuclear cells. RT-PCR was performed on cDNA generated from these RNAs using primers for murine neutrophil gelatinase and b-actin. The arrow indicates the position of the PCR product generated from gelatinase, and the triangle indicates the position of the product amplified from bactin, which was used as an internal control.
Cell line
WT1 potentiates granulocytic differentiation DM Loeb et al augmentation of the survival of lineage-committed progenitor cells. Our data, using an inducible expression system, provide strong evidence that WT1 is mechanistically involved in granulocytic differentiation. We see a pronounced effect on lineage-specific Gr-1 expression, and also a striking effect on the expression of the stage-specific markers LF and gelatinase.
There is evidence in the literature that different isoforms of WT1 have specific functions. In particular, the WT1 (+/+) isoform blocks G-CSF-mediated differentiation of 32D cl3 cells, 19 while our data demonstrate that the WT1 (À/À) isoform accelerates differentiation. To eliminate the possibility that variation among 32D cl3 cultures in different laboratories could account for this difference, we also established several 32D cl3 cell lines constitutively expressing WT1 (+/+). As previously reported, we found the subclones with the highest level of WT1 (+/+) expression to behave in a manner similar to those described by Inoue et al (data not shown). Thus, these two isoforms, WT1 (À/À) and WT1 (+/+), appear to have distinct functions in hematopoietic differentiation in this model system.
Distinct biological effects of different WT1 isoforms is consistent with the finding that mutations resulting in a reversal of the normal predominance of +KTS isoforms compared to -KTS isoforms in the developing kidney cause Frasier syndrome, a disease defined by male pseudohermaphroditism and progressive glomerulopathy. 21, 22 Similarly, although all WT1 isoforms are detected in batch CD34+ hematopoietic progenitor cells, 23 single-cell RT-PCR studies of such cells have demonstrated that some express only a single isoform of WT1. 9 It is possible that CD34+ cells expressing WT1 (+/+) are not yet lineage committed, while cells that express WT1 (À/À) are committed to granulocytic differentiation.
The disparate functions of WT1 isoforms, (+/+) vs (À/À), that have been identified in the 32D cl3 model system are compatible with the biology of hematopoietic stem cells. Stem cells do not normally proliferate, and they must remain undifferentiated despite existing in a milieu that promotes the differentiation of committed progenitors. WT1 (+/+) inhibits a differentiation signal from G-CSF, 19 and WT1 (À/À) downregulates Cyclin E, upregulates p21 WAF1/CIP1 , and at least in the presence of G-CSF slows cell cycle progression. A stem cell that expresses both of these isoforms might therefore be expected to cycle slowly, and to resist the differentiation signals that are acting on neighboring committed progenitors. These complementary effects suggest a crucial role for WT1 in the biology of hematopoietic stem cells. Additionally, stem cells that express a dominant-negative WT1 that interferes with the normal function of WT1 (À/À) may have an impaired ability to differentiate while maintaining a capacity to proliferate, and thus may be more likely to undergo malignant transformation and give rise to AML. Dominant-inhibitory mutations of WT1 have in fact been described in cases of AML. 24, 25 The mechanism by which WT1 potentiates granulocytic differentiation is at present unclear. We have reported that WT1 (À/À) suppresses the Cyclin E promoter, 26 and others have reported that WT1 induces the expression of p21. 27 These findings suggest that WT1 might promote differentiation by inhibiting cell cycle progression, and we did, in fact, observe an effect on the cell cycle in G-CSF-treated cells. We were unable to demonstrate an effect of WT1 (À/À) on known mediators of granulocytic differentiation, such as PU.1 and C/EBPa (data not shown). Future work will seek to determine whether there are specific WT1 (À/À) target genes involved in hematopoietic differentiation.
WT1 (À/À) accelerates G-CSF-induced 32D cl3 differentiation, but in contrast to C/EBPa-ER, does not induce granulopoiesis in 32D cl3 cells cultured in IL-3. 28 This difference likely reflects the ability of C/EBPa to both induce a G1/S cell cycle arrest and to induce the expression of myeloid-specific genes such as MPO and LF, 29 whereas WT1 (À/À) does not induce the expression of myeloid-specific genes. A G1/S arrest may be necessary for terminal phases of granulopoiesis, such as LF expression and nuclear maturation, but is not in and of itself sufficient for this process. Inhibiting G1/S progression using mimosine, an inducer of p27, accelerates induction of LF by G-CSF but is insufficient to trigger differentiation alone (Wang et al, in press ). Furthermore, mutations in C/EBPa that eliminate DNA binding activity result in a protein that slows G1 but does not mediate granulopoiesis in 32D cl3 cells (Wang et al, in press ). In contrast, overexpression of c-Myb in 32D cl3 cells prevents their G1/S cell cycle arrest in response to G-CSF and allows MPO but not LF induction. 30 Strikingly, WT1 (À/À) has the opposite effect in 32D cl3 cells cultured in G-CSF, suppressing Cyclin E and slowing cell cycle progression, and accelerating the induction of LF and gelatinase, without altering MPO induction.
In summary, we have shown that WT1 (À/À) potentiates the granulocytic differentiation of murine hematopoietic progenitor cells. Inhibition of differentiation is critical for the neoplastic transformation of hematopoietic cells, and unraveling the role of WT1 in this process will clarify the role of this gene in leukemogenesis. 32DV4 and 32DWT1 cells were grown in IL-3 or in G-CSF for 2 days, with or without 100 mM ZnCl 2 , and cell cycle analysis was performed using Hoechst 33258 staining. In all, 10 000 events were counted on the FACS machine. The numbers are the percentage of cells in the indicated phase of the cell cycle, or the ratio of cells in G1 to cells in S phase. Numbers in parentheses represent the error.
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